tirzepatide and psoriasis GLP-1 Drug Makes Its Case for Treating Plaque Eli Lilly (LLY) Tests Zepbound

Across STEP-1 and other trials (STEP-3, 4, and 8), average weight loss ranged between 14.9% and 17.4% at 68 weeks

[28] suggest that patients who omitted at least one dose of their GLP-1RA prior to surgery had a lower risk of RGC compared to those maintained on a regular dosing regimen

Side Effects and Safety Profile The 12.5mg adverse profile matches the GLP-1/GIP class, though gastrointestinal (GI) event rates are dose-dependent and occur more frequently than at lower titration steps[1][4]

Designed explicitly for obesity intervention, Wegovy represents a focused approach to weight management, distinct from Mounjaros broader diabetes-centric inception